COPD exacerbations·2: Aetiology

Thorax

Volumn 61, Issue 3, 2006, Pages 250-258

  Sapey, E ^a   Stockley, R A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITROGEN DIOXIDE; OZONE; SULFUR DIOXIDE; BIOLOGICAL MARKER; CYTOKINE; PROTEIN;

AIR POLLUTANT; AIRWAY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; ENVIRONMENTAL EXPOSURE; HUMAN; PARTICULATE MATTER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; BLOOD; BRONCHITIS; METABOLISM; MICROBIOLOGY; POLLUTION; SPUTUM;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; BRONCHITIS; CYTOKINES; ENVIRONMENTAL POLLUTION; HUMANS; PROTEINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; VIRUS DISEASES;

EID: 33645053487     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.041822     Document Type: Review

References (132)

1. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151-5S.
2. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
3. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
4. Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax 2000;55:631-2.
5. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
6. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
7. Rodriguez-Roisin R. Towards a consensus definition for COPD exacerbations. Chest 2000;117:398-401s.
8. Finlay GA, Russell KJ, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52:502-6.
9. Saetta MTG, Facchini FM, Corbino L, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997;156:1633-9.
10. Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000;15:109-15.
11. 1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71.
12. Martin TR, Raghu G, Maunder RJ, et al. The effects of chronic bronchitis and chronic air flow obstruction on lung cell populations recovered by bronchoalveolar lavage. Am Rev Respir Dis 1985;132:260.
13. Traves SL, Culpitt SV, Russell RE, et al. Increased levels of the chemokine GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002;57:590-5.
14. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999;160:893-8.
15. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505-10.
16. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-50.
17. Tsoumakidou M, Tzanakis N, Chrysofakis G, et al. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:572-9.
18. Selby C, Drost E, Lannan S, et al. Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:1359-64.
19. Bhowmik A, Seemungal TAR, Sapsford RJ. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD. Thorax 2000;55:114-20.
20. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001;56:30-5.
21. Hill AT, Bayley D, Campbell EJ, et al. Airways inflammation in chronic bronchitis;the effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000;15:886-90.
22. Gerritsen WB, Asin J, Zonen P, et al. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respir Med 2005;99:84-90.
23. Malo O, Sauleda J, Busquets X, et al. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2002;38:172-6.
24. Stockley RA, O'Brien C, Pye A, et al. Relationship to sputum colour to nature and out-patient management of acute exacerbations of COPD. Chest 2000;117:1638-45.
25. Gompertz S, O'Brien C, Bayley D, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-9.
26. Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-55.
27. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003;58:680-5.
28. Fujimoto K, Yasuo M, Urushibaba K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005;25:640-6.
29. Gerritsen WB, Asin J, Zanen P, et al. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respir Med 2005;99:84-90.
30. van Beurden WJ, Smeenk FW, Harff GA, et al. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. Monaldi Arch Chest Dis 2003;59:273-80.
31. Zhu J, Qiu YS, Majumdar S, et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinphil chemoattractants. Am J Respir Crit Care Med 2001;164:3-4.
32. Foxman EF, Campbell JJ, Butcher EC. Multistep navigation and the combinatorial control of leukocyte chemotaxis. J Cell Biol 1997;139:1349-59.
33. Liou TG, Campbell EJ. Quantum proteolysis resulting from release of single granules by human neutrophils;a novel, nonoxidative mechanism of extracellular proteolytic activity. J Immunol 1996;157:2624-31.
34. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in α-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88:891-7.
35. Stockley RA, Shaw J, Afford SC, et al. Effect of alpha one proteinase inhibitor on neutrophil chemotaxis. Am J Respir Cell Mol Biol 1990;2:163-70.
36. Burnett D. Neutrophils. In: Stockley RA, ed. Pulmonary defenses. Chichester: Wiley Europe, 1997:113-26.
37. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95.
38. Stockley RA, Bayley D, Hill SL, et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001;56:366-72.
39. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000. A state of the art review. Clin Microbiol Rev 2001;14:336-63.
40. Connors AF Jr, Dawson NV, Tomas C, et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understanding Prognosis and Preferences for Outcomes and Risks of Treatment. Am J Respir Crit Care Med 1996;154:959-67.
41. Groenewegen KH, Schols AMWJ, Wouters EFM. Mortality and mortality-related factors after hospitalisation for acute exacerbation of COPD. Chest 2003;124:459-67.
42. Hodgev VA, Kostianev SS, Torosian AA, et al. Long-term changes in dyspnea, lung function and exercise capacity in COPD patients. Folia Med 2004;46:12-7.
43. Spencer S, Calverley PMA, Burge S, Jones PW, ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:122-8.
44. Donaldson GC, Wilkinson TM, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:446-52.
45. Viglio S, Iadarola P, Lupi A, et al. MEKC of desmosine and isodesmosine in urine of chronic detructive lung disease patients. Eur Respir J 2000;15:1039-45.
46. Gottlieb DJ, Stone PJ, Sparrow D, et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function. The Normative Aging Study. Am J Respir Crit Care Med 1996;154:1290-5.
47. Kosmas EN, Zorpidou D, Vassilareas V, et al. Decreased CD4 complement component serum levels correlate with the degree of emphysema in patient with chronic bronchitis. Chest 1997;112:341-7.
48. White AJ, Gompertz S, Stockley RA. The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003;58:73-80.
49. Gompertz S, Bayley DL, Hill SL, et al. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
50. Agerberth B, Grunewald J, Castanos-velez E, et al. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999;160:283-90.
51. Draper DL, Landers DV, Krohn MA, et al. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000;183:1243-8.
52. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5.
53. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108:43-525.
54. Sunyer J, Saez M, Murillo C, et al. Air pollution and emergency room admission for chronic obstructive pulmonary disease. Am J Epidemiol 1993;137:701-5.
55. Monso E, Ruiz J, Manterola J, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995;152:1316-20.
56. Fagon JY, Chastre J, Trouillet JL, et al. Characterisation of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990;142:1004-8.
57. Pela R, Marchesani FF, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations, a bronchoscope investigation. Monaldi Arch Chest Dis 1998;53:262-7.
58. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
59. Bogaert D, van der Valk P, Ramdin R, et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004;72:818-23.
60. Serthi S, Wrona C, Grant BJ, et al. Strain specific immune responses to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:448-53.
61. Murphy TF, Brauer AL, Grant BJ, et al. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 2005;172:195-9.
62. Adler KB, Hendly DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol 1986;125:501-14.
63. Wilson R, Roberts D, Cole P. Effects of bacterial products on human ciliary function in vitro. Thorax 1984;40:125-31.
64. Read RC, Wilson R, Rutman A, et al. Interaction of nontypable Haemophilus influenzae with human respiratory mucosa in vitro. J Infect Dis 1991;163:549-58.
65. Solar N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22.
66. Khair OA, Devalia JL, Abdelaziz MM, et al. Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL-8, TNF-alpha and expression of ICAM-1 in cultured human epithelial cells. Eur Respir J 1994;7:2109-16.
67. Bresser P, Out TA, van Alphen L, et al. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:947-52.
68. Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000;118:193-203.
69. Stockley RA. Chronic obstructive pulmonary disease, neutrophils and bacteria: from science to integrated care pathways. Clin Med 2004;4:567-72.
70. Patel IS, Seemungal TA, Wilkes M, Lloyd-Owen SJ, et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax 2002;57:759-64.
71. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976;113:465-73.
72. McHardy VU, Inglis JM, Calder MA, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Chest 1980;74:228-38.
73. Bandi V, Apicella MA, Mason E, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001;164:2114-9.
74. Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonisation by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:266-72.
75. Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2004;17:113-9.
76. Mobbs KJ, van Saene HK, Sunderland D, et al. Oropharyngeal gram-negative bacillary carriage in chronic obstructive pulmonary disease. Respir Med 1999;93:540-5.
77. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;117:380-5S.
78. Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonisation in chronic obstructive pulmonary disease. Eur Respir J 1999;13:343-8.
79. Packe GE, Hodson ME. Changes in spirometry during consecutive admissions for infective pulmonary exacerbations in adolescent and adult cystic fibrosis. Respir Med 1992;86:45-8.
80. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with branchiectasis: microbial pattern and risk factors. Thorax 2002;57:15-9.
81. Chin CL, Manzel U, Lehman EE, et al. Haemophilus influenzae from COPD patients with exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med 2005;172:85-91.
82. Serthi S, Wrona C, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive disease. N Engl J Med 2002;347:465-71.
83. Carilli AD, Gohd RS, Gordon W. A virological study of chronic bronchitis. N Engl J Med 1964;270:123.
84. Monto AS, Bryan ER. Susceptibility to rhinovirus infection in chronic bronchitis. Am Rev Respir Dis 1978;118:1101-3.
85. Smith CB, Golden C, Kanner RE, et al. Association of viral and mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980;121:225-32.
86. Greenburg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-73.
87. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204-15.
88. Stenhouse AC. Viral antibody levels and clinical status in acute exacerbations of chronic bronchitis: a controlled prospective study. BMJ 1968;3:287-90.
89. Seemungal T, Harper-Owen R, Bhowmik A, et al. Detection of rhinovirus in induced sputum at exacerbation of chronic bronchitis. Eur Respir J 2000;16:677-83.
90. Seemungal TA, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive disease. Am J Respir Crit Care Med 2001;164:1618-23.
91. Glezen WP, Greenberg SB, Ahnar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000;283:499-505.
92. Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-73.
93. Beckham JB, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic obstructive pulmonary disease. J Infect 2005;50:322-30.
94. Centres for Disease Control and Prevention. Influenza. A season summary, 2005. Available at www cdc gov/flu/weeldy/fluactivity/htm.
95. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United Stales. JAMA 2004;292:1333-40.
96. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
97. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-59.
98. Borg I, Rohde G, Loseke S, et al. Evaluation of a quantitative real-time PCR for me detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J 2003;21:944-51.
99. Van den Hoogen BG, van Doornum GJ, Fockens JC, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalised patients. J Infect Dis 2003;188:1571-7.
100. Hegele RG, Hayashi S, Hogg JC, et al. Mechanisms of airway narrowing and hyperesponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995;151:1659-04.
101. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor ICAM-1 via increased NF-κB mediated transcription. J Biol Chem 1999;274:9707-20.
102. Fiorini G, Crespi S, Rinaldi M, et al. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother 2000;54:274-8.
103. Saetta MP, Di Stefano A, Maestrelli P, et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and exacerbations of chronic bronchitis. Clin Exp Allergy 1995;26:766-74.
104. Saetta MP, Di Stefano A, Moestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
105. Spurrell JC, Wiehler S, Zaheer RS, et al. Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol Physiol 2005;289:L85-95.
106. Biagioli MC, Kaul P, Singh I, et al. The role of oxidative stress in rhinovirus induced elaboration of IL-8 by respiratory epithelial cells. Free Radic Biol Med 1999;26:454-62.
107. Mullol J, Baraniuk JN, Logun C, et al. Endothelin-1 induces GM-CSF, IL-6, IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B). Neuropeptides 1996;30:551-6.
108. Jacoby DB. Interaction of viral infections with muscarinic receptors. Clin Exp Immunol 1999;29:59-64.
109. Smith CB, Golden C, Klauber MR, et al. Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 1976;134:552-61.
110. Lieberman D, Lieberman D, Yaakov BM, et al. Infectious etiologies in acute exacerbations of COPD. Diagn Microbiol Infect Dis 2001;40:95-102.
111. Chu HW, Jeyaseelan S, Rino JG, et al. TLR2 signalling is critical for Mycoplasma pneumoniae induced airway mucin expression. J Immunol 2005;174:5713-9.
112. Meloni F, Paschetto E, Mangiarotti P, et al. Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations. J Chemother 2004;16:70-6.
113. Beaty CD, Grayston JT, Wang SP. Chlamydia pnuemoniae, strain TWAR, infections in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;144:1408-10.
114. Rupp J, Kothe H, Mueller A, et al. Imbalanced secretion of IL-1 beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J 2003;22:274-9.
115. Ministry of Health. Mortality and morbidity during the London fog of December 1952, Report No 95 on Public Health and Medical Subjects. London: Ministry of Health, 1954.
116. World Health Organisation. Acute effects on health of smog episodes. Copenhagen: World Health Organisation, 1992.
117. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997;10:1064-71.
118. Cifuentes LA, Vega J, Kopfer K, et al. Effect of the fine fraction of particulate matter versus the course mass and other pollutants on daily morality in Santiago, chile. J Air Waste Manag Assoc 2000;50:1287-98.
119. Dockery DW, Pope CAI, Xu X, et al. An association between air pollution and mortality in six US cities. N Engl J Med 1993;329:1753-9.
120. Dockery DW, Pope CAI, Xu X, et al. An association between air pollution and mortality in six US cities. N Engl J Med 1993;329:1753-9.
121. MacNee W, Donaldson K. Exacerbations of COPD. Environmental mechanisms. Chest 2000;117:390-7s.
122. Pope CA, Kanner RE. Acute effects of PM10 pollution on pulmonary function of smokers with mild to moderate chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;147:1336-40.
123. Pope CAI, Bates DV, Raizenne ME. Health effects of particulate air-pollution. Environ Health Perspect 1995;103:472-80.
124. Jany B, Gallup M, Tsuda T, et al. Mucin gene expression in rat airways following infection and irritation. Biochem Biophys Res Commun 1991;181:1-8.
125. Li XY, Gilmour PS, Donaldson K, et al. Free radical activity and pro-inflammatory effects of particulate air pollution (PM10) in vivo and in vitro. Thorax 1996;51:1216-22.
126. Salvi SS, Nordenhall C, Blomberg A, et al. Acute exposure to diesel exhaust increases IL-8 and GRO-alpha production in healthy human airways. Am J Respir Crit Care Med 2000;161:550-7.
127. Pourazar J, Mudway IS, Samet JM, et al. Diesel exhaust activates redox sensitive transcription factors and kinases in human airways. Am J Physiol Lung Cell Mol Physiol 2005;289:L724-30.
128. Kopp MV, Ulmer C, Ihost G, et al. Upper airway inflammation in children exposed to ambient ozone and potential signs of adaptation. Eur Respir J 1999;14:854-61.
129. Devalia JL, Rusnak C, Herdman MJ, et al. Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation. Lancet 1994;344:1668-71.
130. Donaldson GC, Seemungal T, Jeffries DJ, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J 1999;13:844-9.
131. Wongsurakiat P, Maranetra KN, Gulprasutdilog P, et al. Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study. Respirology 2004;9:550-6.
132. Tata U, West J, Harrison T, et al. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003;58:835-9.